US Stock Insider Trading | QuidelOrtho Discloses 6 Insider Transactions on February 2

K-LinePoet · 2026-02-04T19:01:50+00:00

On February 2, 2026, QuidelOrtho disclosed an insider transaction conducted on January 29, involving six executives including Blaser, who collectively sold 9,755 shares at a price of $27.41, amounting to $486,200. The company focuses on the research, development, and sales of rapid diagnostic solutions, primarily for medical institutions and international markets.

K-LinePoet

2026-02-04 19:01:50

Abstract generation in progress

On February 2, 2026, QuidelOrtho (QDEL) disclosed six insider trading transactions. Executive Blaser Brian J. sold 7,755 shares on January 29, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Bowman Ronald Lee	January 29, 2026	Sell	1,210	27.41	$33,200
February 2, 2026	Executive	Busky Joseph M.	January 29, 2026	Sell	2,602	27.41	$71,300
February 2, 2026	Executive	Siegrist Jonathan Philip	January 29, 2026	Sell	1,009	27.41	$27,700
February 2, 2026	Executive	McLellan Philip D.	January 29, 2026	Sell	2,017	27.41	$55,300
February 2, 2026	Executive	Hodges Michelle A	January 29, 2026	Sell	3,072	27.41	$84,200
February 2, 2026	Executive	Blaser Brian J.	January 29, 2026	Sell	7,755	27.41	$212,600
December 10, 2025	Director	RHOADS ANN D	December 10, 2025	Buy	750	28.28	$21,200
December 1, 2025	Director	Wilkins Joseph D Jr.	November 26, 2025	Buy	370	27.96	$10,300
November 25, 2025	Director	WIDDER KENNETH J	November 25, 2025	Buy	7,021	15.74	$110,500
November 25, 2025	Director	WIDDER KENNETH J	November 25, 2025	Sell	4,026	27.81	$112,000

【Company Information】

QuidelOrtho Corporation was incorporated in Delaware on December 17, 2021. The company is a leader in the development, manufacturing, and marketing of rapid diagnostic testing solutions. These diagnostic tests primarily include applications for infectious diseases, women’s health, and gastrointestinal diseases. The company sells its products directly to end customers and distributors. Regardless of the buyer, these products are intended for professional use, mainly in physician offices, hospitals, clinical laboratories, reference laboratories, major universities, retail pharmacies, and health screening centers. The company markets its products in the United States through national and regional distributors and direct sales channels. Internationally, the company operates through distributor arrangements, mainly selling and marketing its products in Japan and Europe.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.